drugset / Trial / NCT01906541

Gene Therapy for X-CGD

NCT01906541 ↗

Phase 1/2 Unknown 5 enrolled Hubert Serve, Prof., MD
NaSingle-groupOpen-labelTreatment

Summary

X-linked chronic granulomatous disease (X-CGD) is a rare inherited immune defect, which is caused by the inability of phagocytic cells to produce reactive oxygen species due to a defect in the gp91phox subunit of the NADPH oxidase complex. X-CGD patients suffer from recurrent and life-threatening infections and severe hyperinflammatory complications. The only curative treatment for X-CGD is allogenic hematopoietic stem cell transplantation, but this procedure implies severe risks and many patients lack an appropriate donor. Therefore alternative curative approaches are urgently needed. In this study, patients will be treated with gene-corrected autologous CD34+ cells, using a SIN gammaretroviral vector for ex-vivo gene-therapy.

Timeline

Start
2013-07
Primary completion
2013-12
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ex-vivo gene-therapy Cell therapy — —